Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BioNexus Gene Lab (BGLC) EBT (2018 - 2025)

BioNexus Gene Lab's EBT history spans 8 years, with the latest figure at -$708991.0 for Q3 2025.

  • For Q3 2025, EBT rose 47.24% year-over-year to -$708991.0; the TTM value through Sep 2025 reached -$2.4 million, down 157.88%, while the annual FY2024 figure was -$1.6 million, 38.84% up from the prior year.
  • EBT for Q3 2025 was -$708991.0 at BioNexus Gene Lab, down from -$616172.0 in the prior quarter.
  • Across five years, EBT topped out at $370491.0 in Q3 2021 and bottomed at -$2.5 million in Q3 2023.
  • The 5-year median for EBT is -$83689.0 (2024), against an average of -$284824.1.
  • The largest annual shift saw EBT surged 2696.19% in 2021 before it plummeted 3664.13% in 2023.
  • A 5-year view of EBT shows it stood at $197077.0 in 2021, then plummeted by 164.67% to -$127451.0 in 2022, then surged by 298.96% to $253571.0 in 2023, then plummeted by 266.44% to -$422032.0 in 2024, then tumbled by 67.99% to -$708991.0 in 2025.
  • Per Business Quant, the three most recent readings for BGLC's EBT are -$708991.0 (Q3 2025), -$616172.0 (Q2 2025), and -$623327.0 (Q1 2025).